Please login to the form below

Not currently logged in
Email:
Password:

Bayer opens AI-enabled drug discovery center in UK

Seventh LifeHub opens in Reading’s Green Park

Bayer

Bayer has expanded its LifeHub network into the UK to apply artificial intelligence to drug discovery and disease diagnosis.

The German company has established LifeHubs at locations across Asia, Europe and the US. Each site has a different focus but shares a broad goal of connecting Bayer to the scientific community in that area.

Bayer has opened its seventh LifeHub in Reading’s Green Park, thereby bringing the network to the UK for the first time. The facility will focus on the application of AI to healthcare.

“We firmly believe that artificial intelligence has transformative potential for healthcare that can lead to enhancements in prediction, prevention and personalized treatments,” Kemal Malik, Bayer Board Member for Innovation, said in a statement.

That focus will see Bayer work to use AI in the optimisation of data-driven drug discovery. In the near term, Bayer will use the facility to support its existing relationship with clinical AI company Sensyne Health.

Sensyne began working with Bayer to apply AI to the discovery of new cardiovascular disease drugs earlier this year and will now become one of the first companies to move into LifeHub UK.

In conjunction with the opening of LifeHub UK, Bayer disclosed plans to expand its collaboration with Sensyne to cover the development of AI-enabled imaging technologies.

Bayer released the news about LifeHub UK on the same day as it disclosed details of the agreements it has entered into with 11 startups under its G4ADigital Health Partnerships programme.

The 11 companies are split into two groups. One set of companies will board the growth track, giving them a chance to receive €75,000 (£65,000) in funding and the opportunity to work at the headquarters of Bayer’s pharmaceuticals division in Berlin.

The second group of companies are more established. As part of Bayer’s advance track programme, these companies will work to co-create and execute commercial deals. Initial project funding and milestone payments are available to companies on the advance track.

Both tracks are supported by G4A, a programme that brings together all of Bayer’s digital health initiatives. Bayer has supported more than 150 digital health startups since establishing the programme in 2013.

Article by
Phil Taylor

14th October 2019

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Spotlight interview: 15 minutes on insights and market research in pharma
Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma...
WHITE PAPER: The increasing importance of clinical trial marketing advertising in patient recruitment
Learn why advertising is more important than ever in clinical studies...
The 'winner takes all' pricing game
Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s....

Infographics